
Focus on Faculty #83

Nader Sadeghi





Dr. Nader Sadeghi is a Professor in the Department of Otolaryngology-Head and Neck Surgery and the Gerald Bronfman Department of Oncology. He is currently Chair of the Department of Otolaryngology-Head and Neck Surgery at McGill, Chief of the service at the MUHC, and Director of the McGill Integrated Head and Neck Cancer program, leading the program across McGill sites. He is a senior investigator at the Research Institute of the MUHC (RI-MUHC). He graduated with his MD in 1991 followed by residency training in Otolaryngology-Head and Neck Surgery in 1996 both from McGill. He then completed training in epidemiology at McGill followed by a fellowship in head and neck surgical oncology and reconstruction at Rush-Presbyterian-St. Luke's Medical Center in Chicago, Illinois, 1996-1998.

Dr. Sadeghi joined the Department of Otolaryngology-Head and Neck Surgery at McGill and was based at the MUHC from 1998 to 2002 until he was recruited to George Washington University (GWU) in Washington, DC to lead the head and neck cancer program there. He was at GWU for 15 years where he built an integrated multidisciplinary head and neck oncology program. He served as a member of the first board of directors of the Katzen Cancer Research Center at GWU and served as a member of the advisory board committee for the George Washington University Hospital for many years.

Dr. Sadeghi was recruited back to McGill in 2017 to his current position. He is driven by his passion for expanding the clinical and research profile of the Department of Otolaryngology-Head and Neck Surgery and positioning the McGill Integrated Head and Neck Cancer program at the leading edge of innovation and cutting edge of cancer care. He successfully campaigned and negotiated with the Ministère de la Santé et des Services sociaux (MSSS) to bring the Quebec cochlear implant (CI) surgery program to Montreal, and the MUHC is now designated as the CI surgery program for western Quebec. His research interests include translational and clinical research. On cancer care, he has established a new translational head and neck cancer research laboratory at the RI-MUHC within the Functional Genomics group of the Cancer Research Program and recruited a tenure track scientist, Dr. Sampath Loganathan to this newly

formed laboratory. His clinical research currently is focusing on HPV-positive oropharyngeal cancer, neoadjuvant treatment, and transoral robotic surgery. He established the transoral robotic surgery (TORS) program at the MUHC. He has developed and is currently conducting a paradigm-shifting clinical trial for oropharyngeal cancer with neoadjuvant chemotherapy and TORS